Reports indicate that HDAC inhibitors can stimulate LIFR, leading to the acetylation of the LIFR promoter histone, thereby enhancing its expression and causing cancer cell proliferation while preserving dormancy, albeit with more intrusive effects (111, 114). The gene discussed is LIFR; the disease is cancer.